| Reference | </br>1:Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D.Prostate. 2017 Mar;77(4):385-395. doi: 10.1002/pros.23277. Epub 2016 Nov 16. PMID: 27862097 </br>2:Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b<sup>+</sup> Ly6C<sup>hi</sup> cells to tumor tissue reduces tumor growth. Deronic A, Tahvili S, Leanderson T, Ivars F.BMC Cancer. 2016 Aug 8;16(1):610. No abstract available. PMID: 27502070 Free PMC Article</br>3:Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. Nakhlé J, Pierron V, Bauchet AL, Plas P, Thiongane A, Meyer-Losic F, Schmidlin F.Oncoimmunology. 2016 Feb 18;5(6):e1145333. doi: 10.1080/2162402X.2016.1145333. eCollection 2016 Jun. PMID: 27471612 Free PMC Article</br>4:The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth. Deronic A, Leanderson T, Ivars F.BMC Cancer. 2016 Jul 11;16:440. doi: 10.1186/s12885-016-2481-0. Erratum in: BMC Cancer. 2016;16(1):610. PMID: 27400708 Free PMC Article</br>5:Tasquinimod treatment for prostate cancer. Brower V.Lancet Oncol. 2016 Aug;17(8):e322. doi: 10.1016/S1470-2045(16)30272-8. No abstract available. PMID: 27345634 </br>6:Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M.J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13. PMID: 27298414 </br>7:Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. Mehta AR, Armstrong AJ.Ther Adv Urol. 2016 Feb;8(1):9-18. doi: 10.1177/1756287215603558. Review. PMID: 26834836 Free PMC Article</br>8:Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. Olsson A, Nakhlé J, Sundstedt A, Plas P, Bauchet AL, Pierron V, Bruetschy L, Deronic A, Törngren M, Liberg D, Schmidlin F, Leanderson T.J Immunother Cancer. 2015 Dec 15;3:53. doi: 10.1186/s40425-015-0098-5. eCollection 2015. PMID: 26673090 Free PMC Article</br>9:Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment. Magnusson LU, Hagberg Thulin M, Plas P, Olsson A, Damber JE, Welén K.Prostate. 2016 Mar;76(4):383-93. doi: 10.1002/pros.23133. Epub 2015 Dec 10. PMID: 26660725 </br>10:[Tasquinimod: How to act on microenvironment in metastatic prostate cancer]. Houédé N, Irani J.Prog Urol. 2015 May;25(6):298-305. doi: 10.1016/j.purol.2015.01.008. Epub 2015 Feb 13. Review. French. PMID: 25684391
|
